Gender-specific implications for cardiovascular medication use in the elderly: Optimizing therapy for older women

Cardiology in Review

Volumn 11, Issue 5, 2003, Pages 275-298

  Schwartz, Janice B ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiovascular disease; Drug metabolism; Gender; Geriatric pharmacology; Hormone replacement; Pharmacokinetics; Women

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ASTEMIZOLE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 1A; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROMYCIN; ESTROGEN; FIBRINOLYTIC AGENT; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERICUM PERFORATUM EXTRACT; METOPROLOL; MIDAZOLAM; SOTALOL; TERFENADINE; UNINDEXED DRUG; VERAPAMIL;

AGE; AGING; BLEEDING; BODY SIZE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; COUGHING; DIET SUPPLEMENTATION; DISTRIBUTION VOLUME; DRUG CHOICE; DRUG CLEARANCE; DRUG COST; DRUG METABOLISM; DRUG PROTEIN BINDING; ELECTROLYTE DISTURBANCE; HEART ARRHYTHMIA; HORMONE SUBSTITUTION; HUMAN; KIDNEY CLEARANCE; LIVER CLEARANCE; MYOPATHY; PATIENT MONITORING; PHARMACODYNAMICS; POLYPHARMACY; REVIEW; SEX DIFFERENCE; THROMBOSIS; TORSADE DES POINTES;

AGED; BIOLOGICAL AVAILABILITY; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; METABOLIC CLEARANCE RATE; SEX CHARACTERISTICS; TISSUE DISTRIBUTION;

EID: 0041920501     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.crd.0000078842.86834.93     Document Type: Review

References (176)

1. Schmucker D, Vesell E. Underrepresentation of women in clinical drug trials. Clin Pharmacol Ther. 1993;54:11-15.
2. Wizeman T, Pardue M-L, eds. Exploring the Biological Contributions to Human Healtb. Does Sex matter? Washington, DC: Institute of Medicine; 2001. Report No.: ASBN 0-309-07281-6.
3. Harris D, Douglas P. Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med. 2000;343:475-480.
4. FDA. CDER. Report No.: http:www.fda.gov/cder/foi/label2001/207S6lbl.pdf.
5. Chen M-L, Lee S-C, Ng M-J, et al. Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin Pharmacol Ther. 2000;68:510-521.
6. Kang D, Verotta D, Krecic-Shepard M, et al. Population analyses of sustained release verapamil in patients: age, race, and sex effects. Clin Pharmacol Ther. 2003;73:31-40.
7. Krecic-Shepard M, Park K, Barnas C, et al. Race and sex influence clearance of nifedipine: results of a population study. Clin Pharmacol Ther. 2000;68:130-142.
8. Krecic-Shepard M, Barnas C, Slimko J, et al. Gender-effects on verapamil pharmacokinetics and pharmacodynamics in humans. J Clin Pharmacol. 2000;40:219-230.
9. Krecic-Shepard M, Barnas C, Slimko J, et al. In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil. Clin Pharmacol Ther. 1999;66:40-50.
10. Schwartz J, Capili H, Daugherty J. Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1994;55:509-517.
11. Schwartz J, Troconiz I, Verotta D, et al. Aging effects on stereoselective pharmacokinetics and pharmacodynamics of verapamil. J Pharmacol Exp Ther. 1993;265:690-698.
12. Gorski J, Jones D, Haehner-Daniels B, et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther. 1998;64:133-143.
13. Kates R, Keefe D, Schwartz J, et al. Verapamil disposition kinetics in chronic atrial fibrillation. Clin Pharmacol Ther. 1981;30:44-51.
14. Ho P, Triggs E, Bourne D, et al. The effects of age and sex on the disposition of acetylsalicyclic acid and its metabolites. Br J Clin Pharmacol. 1985;19:675-684.
15. Valantine H. Neoral use in the cardiac transplant recipient. Transplant Proc. 2000;32:27S-44S.
16. Fitzsimmons W, Bekerslcy D, Dressler D, et al. Demographic considerations in tacrolimus pharmacokinetics. Transplant Proc. 1998;30:1359-1364.
17. Cullen K, Koehly L, Anderson C, et al. Gender differences in chronic disease risk behaviors through the transition out of high school. Am J Prev Med. 1999;17:1-7.
18. Smit E, Nieto J, Crespo C, et al. Estimates of animal and plant protein intake in US adults: results from the Third National Health and Nutrition Examination Survey, 1988-1991. J Am Diet Assoc. 1999;99:813-820.
19. Van Horn L, Ballew C, Liu K, et al. Diet, body size, and plasma lipids-lipoproteins in young adults: differences by race and sex. The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Epidemiol. 1991;133:9-23.
20. Bailey DG, Spence JD, Munoz C, et al. Interaction of citrus juices with felodipine and nifedipine. Lancet. 1991;337:268-269.
21. Bailey DG, Arnold JMO, Munoz C, et al. Grapefruit juice-felodipine interaction: mechanism, predictability, and effect of naringin. Clin Pharmacol Ther. 1993;53:637-642.
22. Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest. 1997;99:2545-2553.
23. Ernst E, Rand J, Barnes J, et al. Adverse effects profile of the herbal antidepressant St. John's wort. Eur J Clin Pharmacol. 1998;54:589-594.
24. Risk of drug interactions with St. John's wort and indinavir and other drugs. In: www.fda.gov/cder-drugadvisory/stjwort.htm ed: FDA Public Health Advisory; 2000.
25. Schwartz J. Nutraceuticals: sorting out fact, fiction, and uncertainty. J Gend Spec Med. 2000;3:30-37.
26. Samenuk D, Link MS, Homoud MK, et al. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clin Proc. 2002;77:12-16.
27. Boozer C, Nasser J, Heymsfield S, et al. An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. Int J Obes Relat Metab Disord. 2001;25:316-324.
28. Haller C, Benowitz N. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med. 2000;343:1833-1838.
29. Hepatic Toxicity Possibly Associated with Kava-Containing Products - United States, Germany, and Switzerland, 1999-2002. MMWR. 2002;51:1065-1067.
30. Letter to health-care professionals: FDA issues consumer advisory that kava products may be associated with severe liver injury. In: Rockville, Maryland: Food and Drug Administration. US Department of Health and Human Services, Food and Drug Administration; 2002. p. http://www.cfsan.fda.gov/~dms/addskava.html.
31. Ang-Lee M, Moss J, Yuan C-S. Herbal medicines and perioperative care. JAMA. 2001;286:208-216.
32. De Smet P. Herbal Remedies. N Engl J Med. 2002;347:2046-2056.
33. Dias V, Tendler B, Oparil S, et al. Clinical experience with transdermal clonidine in African-American and Hispanic-American patients with hypertension: evaluation from a 12-week prospective, open label clinical trial in community-based clinics. Am J Ther. 1999;6:19-24.
34. Roy S, Flynn G. Transdermal delivery of narcotic analgesics: pH, anatomical, and subject influences on cutaneous permeability of fentanyl and sufentanil. Pharm Res. 1990;7:842-847.
35. Knight V, Yu C, Gilbert B, et al. Estimating the dosage of ribavirin aerosol according to age and other variables. J Infect Dis. 1988;158:443-447.
36. Rohatagi S, Calic F, Harding N, et al. Pharmacokinetics, pharmacodynamics, and safety of inhaled cyclosporin A (ADI628) after single and repeated administration in healthy male and female subjects and asthmatic patients. J Clin Pharmacol. 2000;40:1211-1226.
37. Vahl N, Moller N, Lauritzen T, et al. Metabolic effects and pharmacokinetics of a growth hormone pulse in healthy adults: relation to age, sex, and body composition. J Clin Endocrinol Metab. 1998;82:3612-3618.
38. Beierle I, Meibohm B, Derendorf H. Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther. 1999;37:529-547.
39. Gurwitz J, Gore J, Goldberg R, et al. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2. Ann Intern Med. 1998;129:597-604.
40. Gore J, Granger C, Simoons M, et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation. 1995;92:2811-2118.
41. Van de Werf F, Barron H, Armstrong P, et al. Incidence and predictors of bleeding events after fibrinolytic therapy with fibin-specific agents. Eur Heart J. 2001;22:2253-2261.
42. Van de Werf F. ASSENT-3: implications for future trial design and clinical practice. Eur Heart J. 2002;23:911-912.
43. Verbeeck R, Cardinal J-A, Wallace S. Effect of age and sex on the plasma binding of acidic and basic drugs. Eur J Clin Pharmacol. 1984;27:91-97.
44. Piafsky K, Borga O. Plasma protein binding of basic drugs. Importance of al-acid glycoprotein for interindividual variation. Clin Pharmacol Ther. 1977;22:545-549.
45. Kishino S, Nomura A, Di Z, et al. Alpha-1-acid glycoprotein concentration and the protein binding of disopyramide in healthy subjects. J Clin Pharmacol. 1995;35:510-514.
46. Walle U, Salle S, Bai S, et al. Stereoselective binding of propranolol to human plasma alpha1-acid glycoprotein albumin. Clin Pharmacol Ther. 1983;34:718-723.
47. Gilmore D, Gal J, Gerber J, et al. Age and gender influence the stereoselective pharmacokinetics of propranolol. J Pharmacol Exp Ther. 1992;261:1181-1186.
48. Gleichmann W, Bachmann G, Dengler H, et al. Effects of hormonal contraceptives and pregnancy on serum protein pattern. Eur J Clin Pharmacol. 1973;5:218-225.
49. Keefe D, Yee Y, Kates R. Verapamil protein binding in patients and in normal subjects. Clin Pharmacol Ther. 1981;29:21-26.
50. Krecic-Shepard M, Park K, Slimko J, et al. Gender and race influence clearance of nifedipine, a high affinity cytochrome P450 substrate. J Invest Med. 1998;46:289A.
51. Wilson K. Sex-related differences in drug disposition in man. Clin Pharmacokinet. 1984;9:189-202.
52. Rowland M, Tozer T. Clinical Pharmacokinetics: Concepts and Applications. 3rd ed. Philadelphia: Williams and Wilkins; 1995.
53. Gross J, Friedman R, Azevedo M, et al. Effects of age and sex on glomerular filtration rate measured by 51 Cr-EDTA. Braz J Med Biol Res. 1992;25:129-134.
54. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
55. Levey A, Bosch J, Lewis J, et al. A more accurate method, to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461-470.
56. Yukawa E, Mine H, Higuchi S, et al. Digoxin population pharmacokinetics from routine clinical data: Role of patient characteristics for estimating dosing regimens. J Pharm Pharmacol. 1992;44:761-765.
57. Ducharme M, Slaughter R, Edwards D. Vancomycin pharmacokinetics in a patient population: Effect of age, gender, and body weight. Ther Drug Monit. 1994;16:513-518.
58. Physician's Desk Reference. 55th ed. Montvale, NJ: Medical Economics Company, Inc.; 2001.
59. Staffa J, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002;346:539-540.
60. Rathore S, Wang Y, Krumholz H. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347:1403-11.
61. Eichhorn E, Gheorghiade M. Digoxin - new perspective on an old drug. N Engl J Med. 2002;347:1394-1395.
62. Shlipak M, Heidenreich P, Noguchi H, et al. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med. 2002;137:555-556.
63. Gaudry S, Sitar D, Smyth D, et al. Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine. Clin Pharmacol Ther. 1993;54:23-27.
64. Harris R, Benet L, Schwartz J. Gender effects in pharmacokinetics and pharmacodynamics. Drugs. 1995;50:222-239.
65. Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther. 1999;24:339-346.
66. Fletcher C, Acosta E, Strykowski J. Gender differences in human pharmacokinetics and pharmacodynamics. J Adolesc Health. 1994;15:619-629.
67. Kalow W, Tang B. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase ratios. Clin Pharmacol Ther. 1991;50:508-519.
68. Bock K, Schrenk D, Forster A, et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics. 1994;4:209-218.
69. Relling M, LIn J, Ayers G, et al. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther. 1992;52:643-658.
70. Ou-Yang D-S, Huang S-L, Wang W, et al. Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. Br J Clin Pharmacol. 2000;49:141-151.
71. Kashuba A, Bertino J, Kearns G, et al. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferease-2, and xanthine oxidase activity determined with caffeine phenotyoing. Clin Pharmacol Ther. 1998;63:540-551.
72. Miners J, Attwood J, Birkett D. Influence of sex and oral contraceptive steroids on paracetamol metabolism. Br J Clin Pharmacol. 1983;16:503-509.
73. Kaye C, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet. 2000;39:243-254.
74. Bartoli A, Ziaodong S, Gatti G, et al. The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: a comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate. Ther Drug Monitor. 1996;18:586-591.
75. May DG, Porter J, Wilkinson G, et al. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population. Clin Pharmacol Ther. 1994;55:492-500.
76. Labbe L, Sirois C, PIlote S, et al. Effect of gender, sex hormones, time variables, and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogen. 2000;10:425-438.
77. Walle T, Byington R, Furberg C, et al. Biologic determinants of propranolol disposition. Results from 1308 patients in the beta-blocker heart attack trial. Clin Pharmacol Ther. 1985;38:509-518.
78. Hong-Guang X, Xiu C. Sex differences in pharmacokinetics of oral propranolol in healthy Chinese volunteers. Acta Pharmacologica Sinica. 1995;16:468-470.
79. Jokubaitis L. Development and pharmacology of fluvastatin. Br J Clin Pract Suppl. 1996;77A:11-15.
80. Scripture C, Pieper J. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet. 2001;40:263-281.
81. Vachharajani N, Shyu W, Smith R, et al. The effects of age and gender on the pharmacokinetics of irbesartan. Br J Clin Pharmacol. 1998;46:611-613.
82. Watkins PB, Murray SA, Winkelman LG, et al. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. J Clin Invest. 1989;83:688-697.
83. Thummel KE, O'Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther. 1996;59:491-502.
84. Hunt C, Westerkam W, Stave G. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol. 1992;44:275-283.
85. Greenblatt D, Abernethy D, Locniskar A, et al. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology. 1984;61:27-35.
86. Lew K, Ludwig E, Milad M, et al. Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1993;54:402-414.
87. Hunt C, Strater S, Stave G. Effect of normal aging on the activity of human hepatic cytochrome P450IIE1. Biochem Pharmacol. 1990;40:1666-1669.
88. Krivoruk Y, Kinirons M, Wood A, et al. Metabolism of cytochrome P4503A substrates in vivo administered by the same route: Lack of correlation between alfentanil clearance and erythromycin breath test. Clin Pharmacol Ther. 1994;56:608-614.
89. Greenblatt D, Allen M, Harmatz J, et al. Diazepam disposition determinants. Clin Pharmacol Ther. 1980;27:301-312.
90. Hulst L, Fleishaker J, Peters G, et al. Effect of age and gender on tirilazad pharmacokinetics in humans. Clin Pharmacol Ther. 1994;55:378-384.
91. Kaan B, Kramer W, Wideman C, et al. Demographic factors affecting the pharmacokinetics of cclosporine estimated by radioimmunoassay. Transplantation. 1986;41:459-464.
92. Kinirons M, O'Shea D, Kim R, et al. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther. 1999;66:224-231.
93. Fleishaker JC, Pearson PG, Wienkers LC, Pearson LK, Peters GR. Biotransformation of tirilazad in human: 2. Effect of keoconazole on tirilazad clearance and oral bioavailability. J Pharmacol Exp Ther. 1996;277:991-998.
94. Fleishaker J, Fiedler-Kelly J, Grasela T. Population pharmacokinetics of tirilazad: effects of weight, gender, concomitant phenytoin, and subarachnoid hemorrhage. Pharm Res. 1999;16:575-583.
95. Divoll M, Greenblatt D, Harmatz J, et al. Effect of age and gender on disposition of temazepam. J Pharm Sci. 1981;70:1104-1107.
96. Greenblatt D, Divoll M, Harmatz J, et al. Oxazepam kinetics: effects of age and sex. J Pharmacol Exp Ther. 1980;215:86-91.
97. Walle T, Walle U, Cowart T, et al. Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clin Pharmacol Ther. 1989;46:257-263.
98. Johnson J, Akers W, Herring V, et al. Gender differences in labetalol kinetics: importance of determining stereoisomer kinetics for racemic drugs. Pharmacotherapy. 2000;20:622-628.
99. Morissette P, Albert C, Busque S, et al. In vivo higher glucuronidation of mycophenolic acid in male than in female recipients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil. Ther Drug Monit. 2001;23:520-525.
100. Miners J, Robson R, Birkett D. Gender and oral contraceptive steroids as determinants of drug glucuronidation: effects on clofibric acid elimination. Br J Clin Pharmacol. 1984;18:240-243.
101. Greenblatt D, Abernethy D, Matlis R, et al. Absorption and disposition of ibuprofen in the elderly. Arthritis Rheum. 1984;27:1066-1069.
102. Boudikova B, Szumlanski C, Maidak B, et al. Human liver catechol-O-methltransferase phamacogenetics. Clin Pharmacol Ther. 1990;48:381-389.
103. Fahndrich E, Coper H, Christ W, et al. Erythrocyte COMT activity in patients with affective disorders. Acta Psychiatr. 1980;61:427-437.
104. Floderus Y, Ross S, Wetterberg L. Erythrocyte catechol-O-methyltransferase activity in a Swedish population. Clin Genet. 1981;19:389-392.
105. Halbreich U, Vital-Herne J, Goldstein S, et al. Sex differences in biological factors putatively related to depression. J Affect Disord. 1984;7:223-233.
106. de Vos JW, Geerlings P, van den Brink W, et al. Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. Eur J Clin Pharmacol. 1995;48:361-366.
107. Schuetz E, Furuya K, Schuetz J. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther. 1995;275:1011-1018.
108. Kim R, Leake B, Choo E, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70:189-199.
109. Gorski J, Wang Z, Haehner-Daniesl B, et al. The effect of hormone replacement therapy on CYP3A activity. Clin Pharmacol Ther. 2000;68:412-417.
110. Christy N, Shaver J. Estrogens and the kidney. Kidney Int. 1974;6:366-376.
111. Vaccarino G, Parsons L, Every NR, et al. Sex-based differences in early mortality after myocardial infarction. N Eng J Med. 1999;341:217-225.
112. Vakili B, Kaplan R, Brown D. Sex-based differences in early mortality of patients undergoing primary angioplasty for first acute myocardial infarction. Circulation. 2001;104:3034-3038.
113. Vaccarino VAJ, Veledar E, Weintraub WS. Sex differences in hospital mortality after coronary artery bypass surgery: evidence for a higher mortality in younger women. Circulation. 2002;105:1176-1181.
114. Hochman JS, Tamis JE, Thompson TD, et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med. 1999;341:276-232.
115. Alter D, Naylor C, Austin P, et al. Biology or bias: practice patterns and long-term outcomes for men and women with acute myocardial infarction. J Am Coll Cardiol. 2002;39:1909-1916.
116. Lagerqvist B, Safstrom K, Stahle E, et al. Is early invasive treatment of unstable coronary artery disease equally effective for both women and Men? FRISC II Study Group Investigators. J Am Coll Cardiol. 2001;38:41-48.
117. Blake G, Dada N, Fox J, et al. A prospective evaluation of lipoprotein-associated phospholipase A (2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol. 2001;38:1302-1306.
118. Ridker P, Hennekens C, Buring J, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
119. Kim C, Kwok YS, Saha S, et al. Diagnosis of suspected coronary artery disease in women: a cost-effectiveness analysis. Am Heart J. 1999;137:1019-1027.
120. Kwok Y, Kim C, Grady D, et al. Meta-analysis of exercise testing to detect coronary artery disease in women. Am J Cardiol. 1999;83:660-666.
121. Detrano R, Janosi A, Lyons KP, et al. Factors affecting sensitivity and specificity of a diagnostic test: the exercise thallium scintigram. Am J Med. 1988;84:699-710.
122. Rautaharju P, Zhou S, Wong S, et al. Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol. 1992;8:690-695.
123. Woosley R, Chen Y, Freiman J, et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA. 1993;269:1532-6.
124. Drici M, Knollman B, Wang W, et al. Cardiac actions of erythromycin: influence of female sex. Am Heart J. 1998;131:1184-91.
125. Reinoehl J, Frankovich D, Machado C, et al. Probucol-associated tachyarrhythmic events and QT prolongation: importance of gender. Am Heart J. 1996;131:1184-1191.
126. Wysowski D, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med. 1996;335:290-291.
127. Makkar R, Fromm B, Steinman R, et al. Female gender as a risk factor for torsade de pointes associated with cardiovascular drugs. JAMA. 1993;270:2590-2597.
128. Lehmann MH, Hardy S, Archibald D, et al. Sex difference in risk of torsade de pointes with d,1-sotalol. Circulation. 1996;94:2535-41.
129. Benton R, Sale M, Flockhart D, et al. Greater quinidine-induced QTc interval prolongation in women. Clin Pharmacol Ther. 2000;67:413-418.
130. Torp-Pedersen C, Moller M, Bloch-Thomsen P, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 1999;341:857-865.
131. Rich M. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Ger Soc. 1997;45:968-974.
132. McDonagh T, Morrison C, Lawrence A, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet. 1997;350:829-833.
133. Vasan R, Larson M, Benjamin E, et al. Congestive heart failure in subjects with normal versus reduced let ventricular ejection fraction: prevalence and mortality in a population-based cohort. 1999;33:1948-1955.
134. Masoudi F, Havranek E, Smith G, et al. Gender, age, and heart failure with preserved left ventricular systolic function. J Am Col Cardiol. 2003;41:217-223.
135. Group M-HS. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL. Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2006.
136. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;334:1651-1658.
137. Packer M, Fowler MB, Roecker EB, et al. Effect of Carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation. 2002;106:2194-2199.
138. Simon T, Mary-Krause M, Funck-Brentano C, et al. Sex differences in the prognosis of congestive heart failure. Results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation. 2001;103:375-380.
139. Ghali JK, Pina IL, Gottlieb SS, et al, on Behalf of the MERIT-HF Study Group. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation. 2002;105:1585-1591.
140. Garg R, Yusuf S, Trials CGoAI. Overview of randomized trials of angiotensin converting enzyme inhibitors on mortality and morbidity in heart failure. JAMA. 1995;273:1450-1456.
141. Flather M, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunctin: a systematic overview of data from individual patients. Lancet. 2000;355:1575-1581.
142. Koniaris L, Goldhaber S. Anticoagulation in dilated cardiomyopathy. J Am Coll Cardiol. 1998;31:745-748.
143. Dries D, Rosenberg Y, Waclawi M, et al. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol. 1997;29:1074-1080.
144. Feenstra J, Grobbee D, Remme W, et al. Drug-induced heart failure. J Am Coll Cardiol. 1999;33:1152-1162.
145. Feldman A, Lorell B, Reis S. Trastuzumab in the treatment of metastatic breast cancer. Anticancer therapy vs. cardiotoxicity. Circulation. 2000;102:272-274.
146. Sebastian J, McKinney W, Kaufman J, et al. Angiotensin-converting enzyme inhibitors and cough: prevalence in an outpatient medical clinic population. Chest. 1991;99:36-39.
147. Simon S, Black H, Moser M, et al. Cough and ACE inhibitors. Arch Intern Med. 1992;152:1698-1700.
148. Israeli Z, Hall W. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A Review of the literature and pathophysiology. Ann Intern Med. 1992;117:234-242.
149. Os I, Bratland B, Dahlöf B, et al. Female sex as an important determinant of lisinopril-induced cough. Lancet. 1992;339:372.
150. Lee S, Kim H, et al. Clinical characteristics and angiotensin converting enzyme gene polymorphism in the susceptibility to angiotensin converting enzyme inhibitor-induced cough. Korean Circ J. 1996;26:1099-1106.
151. Lee S-C, Park S, Kim D-K, et al. Iron Supplementation inhibits cough associated with ACE inhibitors. Hypertension. 2001;38:166-170.
152. Lee Y, Tsai J. Angiotensin-converting enzyme gene insertion/deletion, not bradykinin B2 receptor-8T/C gene polymorphism, associated with angiotensin-converting enzyme inhibitor-related cough in Chinese female patients with non-insulin-dependent diabetes mellitus. Metabolism. 2001;50:1346-1350.
153. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke. 1995;26:1471-1477.
154. Morley J, Marinchak R, Rials SJ, et al. Atrial fibrillation, anticoagulation, and stroke. Am J Cardiol. 1996;77:38A-44A.
155. Brass LM, Lichtman JH, Wang Y, et al. Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. Stroke. 2000;31:1802-1811.
156. Becker RC, Hochman JS, Cannon CP, et al. Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study. J Am Coll Cardiol. 1999;33:479-487.
157. Caraballo P, Heit J, Atkinson E, et al. Long-term use of oral anticoagulants and the risk of fracture. Arch Intern Med. 1999;159:1750-1756.
158. Hirsh J. Heparin. N Engl J Med. 1991;324:1565-1574.
159. Chapman M, Hanrahan R, McEwen J, et al. Hyponatraemia and hypokalemia due to indapamide. Med J Aust. 2002;176:219-221.
160. Magrini N, Einarson R, Vaccheri A, et al. Use of lipid-lowering drugs from 1990-1994; an international comparison among Australia, Finland, Italy, Norway and Sweden. Eur J Clin Pharmacol. 1997;53:185-189.
161. McCormack J, Rangno R. An evaluation and critique of the use of lipid-lowering drugs in a population base of 400,000 patients over the age of 65. Can J Clin Pharmacol. 1994;1:27-32.
162. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279:1458-1462.
163. Savoie I, Kazanjian A. Utilization of lipid-lowering drugs in men and women: a reflection of the research evidence? J Clin Epidemiol. 2002;55:95-101.
164. Pasternak R, Smith S, Bairey-Merz C, et al. ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40:568-573.
165. Goldberg A. Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. Am J Cardiol. 1998;82:35-38U.
166. Waters D, Alderman E, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. A randomized controlled trial. JAMA. 2002;288:2432-2440.
167. Kernan W, Viscoli C, Brass L, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med. 2000;343:1826-1832.
168. Flaherty J, Perry HR, Lynchard G, et al. Polypharmacy and hospitalization among older home care patients. J Geronto Med Sci. 2000;55A:M554-M559.
169. Cohen R, Ek K, Pan C. Complementary and alternative medicine (CAM) use by older adults: a comparison of self-report and physician chart documentation. J Geronto Med Sci. 2002;55A: M550-M553.
170. Denham M. Adverse drug reactions. Br Med Bull 1990;46:53-62.
171. Nolan L, O'Malley K. The need for a more rational approach to drug prescribing for elderly people in nursing homes. Age Ageing. 1989;18:52-56.
172. Frezza M, di Padova C, Pozzato G, et al. High blood alcohol levels in women: the role of gastric alcohol dehydrogenase activity and first pass metabolism. N Engl J Med. 1990;322:95-99.
173. Seitz H, Egerer G, Simanowski V, et al. Human gastric alcohol dehydrogenase activity: effect of age sex, and alcoholism. Gut. 1993;34:1433-1437.
174. Kristiansson F. Disposition of alprazolam in human volunteers. Differences between genders. Acta Pharm Nord. 1991;3:249-250.
175. Greenblatt D, Wright C. Clinical pharmacokinetics of alprazolam: therapeutic implications. Clin Pharmacokinet. 1993;24:453-471.
176. Kirkwood C, Moore A, Hayes P, et al. Influence of menstrual cycle and gender on alprazolam pharmacokinetics. Clin Pharmacol Ther. 1991;50:404-409.